Related Experiment Videos
[Astemizole in urticaria--a multicenter study by 412 established dermatologists]
11. Universitäts-Hautklinik Köln.
Zeitschrift Fur Hautkrankheiten
|December 15, 1987
Summary
Astemizole (Hismanal) significantly reduced urticaria severity and pruritus in a large multicenter study. Most patients experienced rapid relief within 24 hours, with a low incidence of side effects.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Urticaria is a common skin condition characterized by itchy welts.
- Effective and well-tolerated treatments are crucial for managing urticaria symptoms.
Purpose of the Study:
- To evaluate the efficacy and safety of astemizole (Hismanal) in treating urticaria patients.
- To assess the onset and peak of action of astemizole in urticaria management.
Main Methods:
- A multicenter study involving 2122 patients treated by 412 dermatologists.
- Patients received astemizole 10 mg daily for 2 weeks.
- Data collected on urticaria severity, pruritus, onset/peak of action, and side effects.
Main Results:
- Severe or moderate urticaria affection decreased from 82.4% to 9.1%.
- Severe or moderate pruritus decreased from 83.9% to 7.8%.
- Rapid onset of action observed in 74% within 24 hours; 5.4% incidence of side effects.
Conclusions:
- Astemizole demonstrates high efficacy and a favorable safety profile for urticaria treatment.
- The drug provides rapid symptom relief, improving patient quality of life.
- Astemizole is a valuable therapeutic option for dermatologists managing urticaria.